跳至主要内容
临床试验/CTRI/2017/12/010726
CTRI/2017/12/010726Other3 期

A Prospective randomized open label study to evaluate the response rate and toxicity of Gefitinib in the treatment of carcinoma cervix patients on chemoradiotherapy

Mysore medical college ad research institute0 个研究点目标入组 23 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
Other
发起方
入组人数
23

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. FIGO stage II to III cervical cancer.
  • 2. Histopathologically proven cervical cancer.
  • 3. Serum creatinine < 1.4mg/dl.

排除标准

  • 1. Pregnant and breast feeding patients.
  • 2. Immunocompromised patients and with Human
  • immunodeficient virsu (HIV) infection.
  • 3. Any allergy to Cisplatin and Gefitinib.
  • 4. Prior surgery for cervical cancer.

研究者

发起方
Mysore medical college ad research institute

相似试验